UOC
BIOA

UBS O'Connor’s BioAmber Inc. BIOA Stock Holding History

UBS O'Connor’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-36,168
Closed -$177K – 534
2013
Q3 		$177K Sell
36,168
-63,832
-64% -$363K ﹤0.01% 357
2013
Q2 		$680K Buy
+100,000
New +$744K 0.01% 398

Other funds holding BIOA

WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
ACPU
Arrowgrass Capital Partners (US) Dover, Delaware $380M AUM 20.87% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
NIMI
Natixis Investment Managers International Paris, France $1.29B AUM 24.83% 1-Year Est. Return

UBS O'Connor's BIOA Position: Q4 2013 in Review

UBS O'Connor sold out of BioAmber Inc. (BIOA) in Q4 2013, closing a stake of 36,168 shares — an estimated $177K sold.

UBS O'Connor first reported a position in BIOA in Q2 2013 and held it in 2 quarters. The position peaked at $680K in Q2 2013. 19 funds tracked by Wall St. Rank hold BIOA as of Q4 2013.

  • UBS O'Connor reported no remaining BioAmber Inc. position as of Q4 2013 after selling out during the quarter.
  • UBS O'Connor sold 36,168 BioAmber Inc. shares in Q4 2013, an estimated $177K.
  • UBS O'Connor first reported a position in BioAmber Inc. in Q2 2013 and held it in 2 quarters.
  • UBS O'Connor's BioAmber Inc. position peaked at $680K in Q2 2013.
  • 19 funds tracked by Wall St. Rank held BioAmber Inc. as of Q4 2013.

Based on UBS O'Connor's 13F filing for Q4 2013, filed 13 Feb 2014.